Savers Value Village (SVV) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Mark Walsh - CEO, President & DirectorMichael Maher - Chief Financial OfficerRandal Konik - Managing DirectorJubran Tanious - President & COOBrooke Roach - Vice President - Equity Research Conference Call Participants Michael Lasser - Equity Research Analyst - Hardlines, Broadlines & Food RetailMatthew Boss - Equity Research AnalystMark Altschwager - Senior Research AnalystPeter Keith - Managing Director & Senior ...

OneSpan (OSPN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Joe Maxa - VP, IRVictor Limongelli - CEOJorge Martell - CFOTrevor Rambo - Software Equity Research Associate Conference Call Participants Catharine Trebnick - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystRudy Kessinger - Managing Director - Senior Equity Research Analyst Operator thank you for standing by. Welcome to the Q1 twenty twenty five OneSpan Earnings Conference Call. At this time, all partic ...

Financial Data and Key Metrics Changes - The company reported total revenues of $74.1 million for Q1 2025, a 61% increase compared to $46 million in Q1 2024 [20] - Net sales revenue for IBSRELA was $44.4 million, reflecting a 57% increase year-over-year [20] - Exposa generated net sales revenue of $23.4 million, up approximately 55% from $15.2 million in the same quarter last year [21] - The company recorded a net loss of approximately $41.1 million or $0.17 per share, compared to a net loss of $26.5 million or $0.11 per share in the prior year [24] Business Line Data and Key Metrics Changes - IBSRELA experienced strong prescription demand, with one of the highest prescription demand quarters to date during Q1 [7] - Exposa grew by 30% year-over-year when excluding a one-time gross to net adjustment for return reserve release [9][15] - The gross to net deduction for IBSRELA was 34.8%, expected to improve throughout the year [21] Market Data and Key Metrics Changes - The IBS C market traditionally contracts in Q1, which was observed this year, but the company remains optimistic about recovery in subsequent quarters [12][30] - The dialysis market is undergoing significant disruption due to the loss of Medicare Part D coverage for phosphate-lowering therapies, impacting Exposa's market dynamics [10] Company Strategy and Development Direction - The company is focused on executing its strategic priorities, driving strong commercial execution for IBSRELA, and navigating access complexities for Exposa [11] - The company aims to achieve peak annual net sales revenue of over $1 billion for IBSRELA and $750 million for Exposa [25][92] - The company is building a pipeline to unlock long-term growth while maintaining a commitment to patient-centric innovation [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IBSRELA and Exposa, citing strong demand and effective commercial strategies [6][20] - The company is closely monitoring market dynamics and will provide updates as the landscape evolves [10] - Management emphasized the importance of building clinical conviction among healthcare providers and enhancing patient access [8][17] Other Important Information - The company received a $5 million milestone payment from a partner in China following the approval of a cannabinoid for hyperphosphatemia [23] - Research and development expenses increased to $14.9 million, reflecting greater engagement with scientific and medical communities [23] Q&A Session Summary Question: Expectations for the IBS C market improvement in Q2 - Management expects the IBS C market to improve as the year progresses, despite the traditional contraction seen in Q1 [30] Question: Clarification on return reserve and its impact on sales - The return reserve was deemed unnecessary due to zero returns and limited bottles in distribution, leading to modest improvements in gross to net going forward [29] Question: Insights on the contraction in Q1 and its comparison to previous years - The market has consistently contracted in Q1, but the company is pleased with its performance relative to others in the market [35][36] Question: Long-term gross to net targets and updates on the China launch - The long-term guidance for gross to net is expected to be around 30% plus or minus 5% [40] Question: Discrepancy between reported revenue and script data - Management acknowledged fluctuations in scripts and emphasized the importance of focusing on guidance rather than individual quarter performance [48][50] Question: Updates on the Patient Assistance Program and commercial trends - The Patient Assistance Program has been effective in helping patients access Exposa, and the company is focused on driving non-Medicare business [75][78] Question: Strategy for expanding Exposa uptake in non-Medicare channels - The strategy involves focusing on Medicaid and commercial channels, with a closed distribution system to manage patient access effectively [108]

Barfresh Food Group (BRFH) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Riccardo Delle Coste - Founder, Chairman, President & CEOLisa Roger - Chief Financial OfficerAnthony Vendetti - Executive Managing Director Conference Call Participants None - Analyst Operator Good afternoon, everyone, and thank you for participating on today's first quarter twenty twenty five corporate update call for Barfresh Food Group. Joining us today is Barfresh Food Group's Founder and CEO, Ricardo Dele Cos ...

GSI (GSIT) Q4 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Lee-Lean Shu - Co-Founder, President, CEO & ChairmanDidier Lasserre - VP, SalesDouglas Schirle - CFOJeffrey Bernstein - Partner Conference Call Participants None - Analyst Operator Welcome to GSI Technologies Fourth Quarter and Fiscal Year twenty twenty five Results Conference Call. At this time, all participants are on a listen only mode. Later, we will conduct a question and answer session. At that time, we will provide instruc ...

Financial Data and Key Metrics Changes - First quarter revenues were $34,900,000, an increase of 10% compared to the prior year [5][13] - Recurring revenues grew 10% to $33,200,000, representing 95% of total revenue [13][29] - Gross profit increased by 9% to $24,600,000, with gross margins consistent at 71% [15][16] - Net loss for the first quarter was $2,400,000 compared to a net loss of $308,000 in the prior period [16] - Adjusted EBITDA increased to $7,300,000 from $6,800,000 in the prior year, with an adjusted EBITDA margin of 21% [16] Business Line Data and Key Metrics Changes - Strong performance from payroll tax management products and contributions from payroll benefits and marketplace offerings [6][29] - HR compliance remains depressed due to the wind down of the ERTC program, but expected to improve in the second half of 2025 [15][29] - Assure Pay is witnessing positive trends, with over 70% of active card users utilizing it more than three times per month [9][29] Market Data and Key Metrics Changes - Contracted revenue backlog increased by 339% year over year to $82,000,000 [11][29] - The company has modeled conservatively for employment growth and potential interest rate cuts [27] Company Strategy and Development Direction - The company is focused on a multi-pronged growth strategy, including organic and inorganic methods [10][19] - Plans to continue expanding product offerings and cross-selling opportunities to existing clients [10][25] - A new $60,000,000 credit facility was finalized to support acquisitions and growth initiatives [18][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's resilience despite macroeconomic uncertainties [27][46] - The company anticipates accelerated revenue growth in the second half of 2025, driven by improved attach rates and backlog [20][88] - Management believes the worst is over regarding HR compliance issues related to ERTC, with expectations for recovery in the second half of the year [40][42] Other Important Information - The company has made 16 acquisitions over the past eighteen months, primarily focused on customer acquisition [19] - The introduction of new benefit solutions, including a 401(k) solution, is contributing positively to revenue growth [17] Q&A Session Summary Question: What are you seeing in terms of productivity with dedicated sales teams? - Management highlighted that attach rates have improved, and dedicated sales specialists are expected to drive further growth [34][35] Question: How is HR compliance performing with ERTC and HR compliance bundles? - Management noted that retention rates had declined but are expected to improve in the second half of 2025 as the cohort stabilizes [39][42] Question: Any impact from tariffs on pipeline and economic uncertainty? - Management indicated that while there are some crosswinds, the small business segment remains active and pipeline metrics are positive [46][48] Question: Can you elaborate on the investments and product roadmap? - Management discussed recent acquisitions and the development of new products, emphasizing a focus on cross-selling and operational efficiency [55][60] Question: What is the outlook for acquisitions with the new credit facility? - Management confirmed two acquisitions in the first quarter and expects an increase in acquisition activity in the second half of the year [70][72] Question: How should we think about tax deals ramping into revenue? - Management indicated that contracted backlog is a key indicator, with expectations for larger deals in the second half of the year [75][76] Question: Can you provide updates on the Canada tax product and competition? - Management reported a strong early pipeline for the Canadian tax product and noted that interest levels are high in the competitive environment [99][101]

Cohu (COHU) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Jeffrey Jones - VP, Finance & CFOLuis Müller - President, CEO & Board MemberBrian Chin - DirectorDavid Duley - Managing PrincipalCraig Ellis - Director of ResearchRobert Mertens - Equity Research Associate Conference Call Participants Charles Shi - Senior AnalystTyler Burmeister - Equity Research Analyst Operator Good day, and thank you for standing by. Welcome to Cohu's First Quarter twenty twenty five Financial Results Call. A ...

Travere Therapeutics (TVTX) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Victoria Prescott - Investor RelationsEric Dube - President and Chief Executive OfficerJula Inrig - Chief Medical OfficerPeter Heerma - Chief Commercial OfficerChris Cline - Chief Financial OfficerWilliam Rote - Chief Research OfficerWill Soghikian - Vice President - Equity ResearchLaura Chico - Managing Director, Equity ResearchLiisa Bayko - Managing DirectorGreg Harrison - Director - BiotechnologySadia Rahman - ...

iRhythm (IRTC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor RelationsQuentin Blackford - President, CEO & DirectorDaniel Wilson - CFOAllen Gong - Vice PresidentMacauley Kilbane - Equity Research AssociateSuraj Kalia - Managing DirectorJon Young - DirectorRichard Newitter - Managing Director Conference Call Participants Kallum Titchmarsh - AnalystNone - AnalystNathan Treybeck - AnalystDavid Rescott - Senior Research AnalystDavid Saxon - Senio ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 22% year-over-year, reaching $169 million, with surgical revenue growing by 24% to $152 million [4][9] - Adjusted EBITDA for the first quarter was $11 million, marking a 6% margin and an improvement of over 800 basis points compared to the previous year [13][14] - Non-GAAP gross margin was 70%, down 50 basis points year-over-year but up 70 basis points sequentially [11] Business Line Data and Key Metrics Changes - Surgical revenue grew by 24% year-over-year, driven by a 17% increase in procedural volume and an 18% increase in the number of surgeons utilizing ATEC procedures [6][10] - EOS revenue increased by 8% year-over-year, with a record order volume leading to a 28% year-over-year increase in the order book [11][12] Market Data and Key Metrics Changes - Established territories saw a revenue growth of 23%, indicating strong surgeon and territory penetration [6] - Same store sales from sales agents in territories for over a year grew by 23% year-over-year, reflecting significant growth in established markets [12][84] Company Strategy and Development Direction - The company is focused on creating clinical distinction through innovative procedural solutions that improve patient outcomes [24][25] - ATEC aims to expand its sales force and enhance operational efficiency to drive growth and profitability [6][23] - The strategy includes leveraging informatics to reduce surgical variables and improve predictability in spine surgery [26][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity for the full year 2025, with expectations of continued strong revenue growth [19][17] - The company anticipates a revenue outlook of approximately $734 million for 2025, with surgical revenue growth of 21% [19][21] - Management noted that the spine market remains resilient despite economic uncertainties, with high demand for their products [106][107] Other Important Information - The company successfully refinanced its 2026 convertible note, extending maturity and maintaining a low coupon rate [17] - The first quarter cash burn was at the low end of the expected range, indicating improved cash management [15][16] Q&A Session Summary Question: Market size and competitive dynamics for the new Corpectomy system - Management indicated that they are the only company offering this procedure in the prone position, which provides unique advantages [41][42] Question: Tariff exposure in 2025 - The company expects low single-digit million impacts on cost of goods sold due to tariffs, primarily affecting EOS equipment [54][55] Question: Update on robot launch plan - The robot is in the alpha phase, with plans for an end-of-year launch, and integration with navigation systems is underway [60][61] Question: Cash outlay trends - The company achieved a cash use of $15 million in Q1, with expectations for positive cash flow in subsequent quarters [65][66] Question: Salesforce productivity and opportunities - Same store sales grew by 23%, indicating strong performance from established sales agents [83][84] Question: EOS placements and portfolio pull-through - Most EOS placements are in new accounts, with a focus on expanding into complex procedures [88][90] Question: Overall volumes and ASC growth - The market is healthy, with surgical volumes growing significantly, and ASCs are expected to evolve over time [93][94] Question: International market expansion - The company remains bullish on international markets, particularly Australia and New Zealand, while maintaining a focused approach [110]